29:
476:
Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C (October 2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin".
88:
222:
310:
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants,
51:
433:
Planès A (September 2003). "Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism".
1309:
547:
639:
371:
Chapman TM, Goa KL (2003). "Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis".
291:
1423:
794:
590:
287:
1404:
812:
785:
525:
299:
739:
422:(in German). Vienna: Österreichischer Apothekerverlag. 2018. Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen.
1472:
540:
1023:
255:
1440:
1114:
834:
294:; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or
1196:
1170:
1162:
533:
519:
1428:
69:
777:
701:
76:
1305:
1367:
946:
901:
131:
757:
149:
1048:
458:
396:
28:
1210:
613:
608:
1467:
1292:
1063:
1053:
1043:
1038:
1033:
1008:
581:
568:
560:
494:
450:
388:
319:
41:
1266:
1097:
1058:
486:
442:
380:
113:
61:
158:
1070:
267:
121:
1434:
961:
647:
556:
339:
323:
271:
251:
1461:
1391:
1361:
951:
936:
931:
892:
564:
515:
400:
384:
275:
80:
462:
1381:
1351:
1329:
1324:
1297:
1246:
1225:
1075:
1014:
970:
847:
790:
729:
724:
705:
603:
572:
490:
101:
96:
20:
1251:
1179:
1148:
1080:
981:
975:
965:
868:
662:
652:
335:
1356:
1273:
1256:
1241:
1220:
1205:
1200:
1143:
1128:
1102:
1092:
1087:
941:
910:
842:
822:
800:
689:
673:
669:
618:
446:
343:
210:
189:
1344:
1339:
1319:
1314:
1261:
1215:
1189:
1184:
1133:
991:
914:
878:
852:
817:
805:
767:
762:
752:
714:
684:
679:
657:
623:
598:
351:
55:
498:
454:
392:
1138:
1123:
956:
927:
918:
906:
873:
719:
347:
295:
169:
178:
1409:
1399:
1376:
1174:
1003:
747:
311:
1371:
633:
315:
1278:
286:
The medication is contraindicated in patients with a history of
529:
338:, bemiparin is classified as an ultra-LMWH because of its low
229:
270:
after surgery, and to prevent blood clotting in the
1390:
1291:
1234:
1161:
1113:
1002:
990:
900:
891:
861:
833:
776:
738:
700:
632:
589:
580:
209:
204:
188:
168:
148:
143:
130:
120:
112:
87:
68:
50:
40:
35:
350:activity than classical LMWHs and act mainly on
346:has 4500 g/mol.) These heparins have lower anti-
157:
541:
8:
19:
999:
897:
586:
548:
534:
526:
27:
518:at the U.S. National Library of Medicine
266:Bemiparin is used for the prevention of
363:
177:
292:disseminated intravascular coagulation
18:
60:
7:
414:
412:
410:
100:
46:Badyket, Ivor, Hibor, Zibor, others
14:
435:Expert Opinion on Pharmacotherapy
354:, reducing the risk of bleeding.
1163:Direct thrombin (IIa) inhibitors
591:Glycoprotein IIb/IIIa inhibitors
385:10.2165/00003495-200363210-00009
288:heparin-induced thrombocytopenia
786:Thromboxane synthase inhibitors
300:subacute bacterial endocarditis
491:10.1016/j.thromres.2011.03.001
1:
256:low molecular weight heparins
1024:Low-molecular-weight heparin
835:Phosphodiesterase inhibitors
748:Acetylsalicylic acid/Aspirin
254:and belongs to the group of
342:of 3600 g/mol on average. (
1489:
205:Chemical and physical data
1418:
996:(with some II inhibition)
447:10.1517/14656566.4.9.1551
298:impairment; and acute or
219:
215:3600 g/mol (average)
26:
520:Medical Subject Headings
62:International Drug Names
1306:Plasminogen activators
778:Thromboxane inhibitors
702:Prostaglandin analogue
250:, among others) is an
77:Subcutaneous injection
1368:serine endopeptidases
902:Vitamin K antagonists
1473:Organic sodium salts
1115:Direct Xa inhibitors
947:Ethyl biscoumacetate
813:Receptor antagonists
758:Carbasalate calcium
479:Thrombosis Research
23:
1445:Never to phase III
1293:Thrombolytic drugs
1009:glycosaminoglycans
582:Antiplatelet drugs
569:antiplatelet drugs
320:antiplatelet drugs
1455:
1454:
1287:
1286:
1157:
1156:
887:
886:
282:Contraindications
237:
236:
16:Chemical compound
1480:
1267:Drotrecogin alfa
1247:Antithrombin III
1098:Dermatan sulfate
1071:Oligosaccharides
1000:
898:
634:ADP receptor/P2Y
587:
550:
543:
536:
527:
503:
502:
473:
467:
466:
430:
424:
423:
416:
405:
404:
368:
290:with or without
233:
232:
225:
181:
161:
135:
104:
64:
31:
24:
22:
21:Bemiparin sodium
1488:
1487:
1483:
1482:
1481:
1479:
1478:
1477:
1458:
1457:
1456:
1451:
1450:
1435:Clinical trials
1414:
1386:
1296:
1283:
1230:
1153:
1109:
1012:
1007:
995:
986:
962:1,3-Indandiones
904:
883:
857:
829:
772:
734:
696:
648:Thienopyridines
637:
628:
576:
557:Antithrombotics
554:
512:
507:
506:
475:
474:
470:
432:
431:
427:
418:
417:
408:
379:(21): 2357–77.
370:
369:
365:
360:
332:
324:corticosteroids
308:
284:
268:thromboembolism
264:
228:
226:
223:(what is this?)
220:
200:
184:
164:
133:
126:96% (estimated)
122:Bioavailability
114:Pharmacokinetic
108:
71:
17:
12:
11:
5:
1486:
1484:
1476:
1475:
1470:
1460:
1459:
1453:
1452:
1449:
1448:
1447:
1446:
1443:
1432:
1426:
1420:
1419:
1416:
1415:
1413:
1412:
1407:
1402:
1396:
1394:
1388:
1387:
1385:
1384:
1379:
1374:
1364:
1359:
1354:
1349:
1348:
1347:
1342:
1334:
1333:
1332:
1327:
1322:
1317:
1302:
1300:
1289:
1288:
1285:
1284:
1282:
1281:
1276:
1271:
1270:
1269:
1259:
1254:
1249:
1244:
1238:
1236:
1232:
1231:
1229:
1228:
1223:
1218:
1213:
1208:
1203:
1194:
1193:
1192:
1187:
1182:
1167:
1165:
1159:
1158:
1155:
1154:
1152:
1151:
1146:
1141:
1136:
1131:
1126:
1120:
1118:
1111:
1110:
1108:
1107:
1106:
1105:
1100:
1095:
1085:
1084:
1083:
1078:
1068:
1067:
1066:
1061:
1056:
1051:
1046:
1041:
1036:
1031:
1020:
1018:
997:
988:
987:
985:
984:
978:
973:
968:
959:
954:
949:
944:
939:
934:
924:
922:
895:
893:Anticoagulants
889:
888:
885:
884:
882:
881:
876:
871:
865:
863:
859:
858:
856:
855:
850:
845:
839:
837:
831:
830:
828:
827:
826:
825:
820:
810:
809:
808:
803:
798:
782:
780:
774:
773:
771:
770:
765:
760:
755:
750:
744:
742:
740:COX inhibitors
736:
735:
733:
732:
727:
722:
717:
711:
709:
698:
697:
695:
694:
693:
692:
687:
682:
667:
666:
665:
660:
655:
644:
642:
635:
630:
629:
627:
626:
621:
616:
611:
606:
601:
595:
593:
584:
578:
577:
565:anticoagulants
555:
553:
552:
545:
538:
530:
524:
523:
511:
510:External links
508:
505:
504:
468:
441:(9): 1551–61.
425:
406:
362:
361:
359:
356:
340:molecular mass
331:
328:
307:
304:
283:
280:
272:extracorporeal
263:
260:
252:antithrombotic
235:
234:
217:
216:
213:
207:
206:
202:
201:
199:
198:
194:
192:
186:
185:
183:
182:
174:
172:
166:
165:
163:
162:
154:
152:
146:
145:
141:
140:
137:
128:
127:
124:
118:
117:
110:
109:
107:
106:
93:
91:
85:
84:
74:
72:administration
66:
65:
58:
48:
47:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
1485:
1474:
1471:
1469:
1466:
1465:
1463:
1444:
1442:
1439:
1438:
1436:
1433:
1430:
1427:
1425:
1422:
1421:
1417:
1411:
1408:
1406:
1403:
1401:
1398:
1397:
1395:
1393:
1392:Non-medicinal
1389:
1383:
1380:
1378:
1375:
1373:
1369:
1365:
1363:
1362:Streptokinase
1360:
1358:
1355:
1353:
1350:
1346:
1343:
1341:
1338:
1337:
1335:
1331:
1328:
1326:
1323:
1321:
1318:
1316:
1313:
1312:
1311:
1307:
1304:
1303:
1301:
1299:
1298:fibrinolytics
1294:
1290:
1280:
1277:
1275:
1272:
1268:
1265:
1264:
1263:
1260:
1258:
1255:
1253:
1250:
1248:
1245:
1243:
1240:
1239:
1237:
1233:
1227:
1224:
1222:
1219:
1217:
1214:
1212:
1209:
1207:
1204:
1202:
1198:
1195:
1191:
1188:
1186:
1183:
1181:
1178:
1177:
1176:
1172:
1169:
1168:
1166:
1164:
1160:
1150:
1147:
1145:
1142:
1140:
1137:
1135:
1132:
1130:
1127:
1125:
1122:
1121:
1119:
1116:
1112:
1104:
1101:
1099:
1096:
1094:
1091:
1090:
1089:
1086:
1082:
1079:
1077:
1074:
1073:
1072:
1069:
1065:
1062:
1060:
1057:
1055:
1052:
1050:
1047:
1045:
1042:
1040:
1037:
1035:
1032:
1030:
1027:
1026:
1025:
1022:
1021:
1019:
1016:
1010:
1005:
1001:
998:
993:
989:
983:
979:
977:
974:
972:
969:
967:
963:
960:
958:
955:
953:
952:Phenprocoumon
950:
948:
945:
943:
940:
938:
937:Coumatetralyl
935:
933:
932:Acenocoumarol
929:
926:
925:
923:
920:
916:
912:
908:
903:
899:
896:
894:
890:
880:
877:
875:
872:
870:
867:
866:
864:
860:
854:
851:
849:
846:
844:
841:
840:
838:
836:
832:
824:
821:
819:
816:
815:
814:
811:
807:
804:
802:
799:
796:
792:
789:
788:
787:
784:
783:
781:
779:
775:
769:
766:
764:
761:
759:
756:
754:
751:
749:
746:
745:
743:
741:
737:
731:
728:
726:
723:
721:
718:
716:
713:
712:
710:
707:
703:
699:
691:
688:
686:
683:
681:
678:
677:
675:
671:
668:
664:
661:
659:
656:
654:
651:
650:
649:
646:
645:
643:
641:
638:
631:
625:
622:
620:
617:
615:
612:
610:
607:
605:
602:
600:
597:
596:
594:
592:
588:
585:
583:
579:
574:
570:
566:
562:
561:thrombolytics
558:
551:
546:
544:
539:
537:
532:
531:
528:
521:
517:
514:
513:
509:
500:
496:
492:
488:
484:
480:
472:
469:
464:
460:
456:
452:
448:
444:
440:
436:
429:
426:
421:
420:Austria-Codex
415:
413:
411:
407:
402:
398:
394:
390:
386:
382:
378:
374:
367:
364:
357:
355:
353:
349:
345:
341:
337:
329:
327:
325:
321:
317:
313:
305:
303:
301:
297:
293:
289:
281:
279:
277:
276:haemodialysis
273:
269:
261:
259:
257:
253:
249:
245:
242:(trade names
241:
231:
224:
218:
214:
212:
208:
203:
196:
195:
193:
191:
187:
180:
176:
175:
173:
171:
167:
160:
156:
155:
153:
151:
147:
142:
138:
136:
129:
125:
123:
119:
115:
111:
103:
98:
95:
94:
92:
90:
86:
82:
81:haemodialysis
78:
75:
73:
67:
63:
59:
57:
53:
49:
45:
43:
39:
36:Clinical data
34:
30:
25:
1382:Fibrinolysin
1352:Anistreplase
1330:Desmoteplase
1325:Tenecteplase
1226:Ximelagatran
1076:Fondaparinux
1028:
1015:antithrombin
971:Diphenadione
848:Dipyridamole
791:Dipyridamole
730:Treprostinil
725:Prostacyclin
604:Eptifibatide
485:(4): 361–7.
482:
478:
471:
438:
434:
428:
419:
376:
372:
366:
333:
309:
306:Interactions
285:
265:
262:Medical uses
247:
243:
239:
238:
227:
221:
132:Elimination
79:(except for
1431:from market
1252:Defibrotide
1180:Bivalirudin
1149:Rivaroxaban
1088:Heparinoids
1081:Idraparinux
982:Tioclomarol
976:Phenindione
966:Clorindione
869:Cloricromen
663:Ticlopidine
653:Clopidogrel
336:semuloparin
274:circuit in
144:Identifiers
42:Trade names
1462:Categories
1357:Monteplase
1274:Ramatroban
1257:Nafamostat
1242:Abelacimab
1221:Melagatran
1206:Dabigatran
1201:Argatroban
1144:Otamixaban
1129:Betrixaban
1117:("xabans")
1103:Sulodexide
1093:Danaparoid
1064:Tinzaparin
1054:Parnaparin
1049:Nadroparin
1044:Enoxaparin
1039:Dalteparin
1034:Certoparin
994:inhibitors
942:Dicoumarol
843:Cilostazol
823:Terutroban
801:Picotamide
690:Ticagrelor
674:nucleoside
670:Nucleotide
640:inhibitors
619:Sibrafiban
358:References
344:Enoxaparin
314:and other
211:Molar mass
190:ChemSpider
159:91449-79-5
150:CAS Number
1441:Phase III
1429:Withdrawn
1345:Urokinase
1340:Saruplase
1320:Reteplase
1315:Alteplase
1262:Protein C
1216:Inogatran
1211:Efegatran
1197:Univalent
1190:Lepirudin
1185:Desirudin
1134:Darexaban
1059:Reviparin
1029:Bemiparin
992:Factor Xa
928:Coumarins
905:(inhibit
879:Vorapaxar
853:Triflusal
818:Terbogrel
806:Terbogrel
795:+ aspirin
768:Triflusal
763:Indobufen
753:Aloxiprin
715:Beraprost
685:Elinogrel
680:Cangrelor
658:Prasugrel
624:Tirofiban
614:Roxifiban
609:Orbofiban
599:Abciximab
516:bemiparin
401:195692039
352:factor Xa
330:Chemistry
240:Bemiparin
139:5–6 hours
134:half-life
70:Routes of
56:Drugs.com
1468:Heparins
1171:Bivalent
1139:Edoxaban
1124:Apixaban
957:Warfarin
874:Ditazole
720:Iloprost
676:analogs
499:21458847
463:13566575
455:12943485
393:14524738
348:thrombin
296:pancreas
258:(LMWH).
230:(verify)
170:DrugBank
89:ATC code
1410:Oxalate
1400:Citrate
1377:Brinase
1175:Hirudin
1004:Heparin
980:Other:
312:aspirin
179:DB09258
105:)
99: (
97:B01AB12
1424:WHO-EM
1372:Ancrod
1366:Other
1013:(bind
1006:group/
522:(MeSH)
497:
461:
453:
399:
391:
322:, and
316:NSAIDs
1310:r-tPA
1235:Other
862:Other
459:S2CID
397:S2CID
373:Drugs
334:Like
248:Zibor
1405:EDTA
1336:UPA
1279:REG1
706:PGI2
567:and
495:PMID
451:PMID
389:PMID
246:and
244:Ivor
197:none
116:data
52:AHFS
911:VII
573:B01
571:) (
487:doi
483:128
443:doi
381:doi
102:WHO
1464::
1437::
1370::
1308::
1199::
1173::
964::
930::
917:,
915:IX
913:,
909:,
907:II
636:12
563:,
493:.
481:.
457:.
449:.
437:.
409:^
395:.
387:.
377:63
375:.
326:.
318:,
302:.
278:.
1295:/
1017:)
1011:/
921:)
919:X
797:)
793:(
708:)
704:(
672:/
575:)
559:(
549:e
542:t
535:v
501:.
489::
465:.
445::
439:4
403:.
383::
83:)
54:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
